Regentis Biomaterials Ltd. (RGNT) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Regentis Biomaterials Ltd. (RGNT) stock forecast summary
On Oct. 13, 2026, RGNT is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5379 stocks scored that day.
Regentis Biomaterials Ltd. is a small-cap company with a market capitalization of $8M. It ranks number 21 by market capitalization among the 24 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for RGNT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, RGNT included.
Follow RGNT freeRGNT price chart and AI forecast
How RGNT ranks among 5379 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Regentis Biomaterials Ltd. (RGNT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.
Valuation & Market
| Metric | RGNT | Rank |
|---|---|---|
| Market Cap | $8M | 21/24 |
| P/B Ratio | 4.40x | 8/19 |
| Book Value/Share | $0.37 | – |
Financial Health
| Metric | RGNT | Rank |
|---|---|---|
| D/E Ratio | 0.61x | 14/23 |
| Financial Leverage | 1.61x | 14/23 |
| Interest Coverage | -88.2x | 14/21 |
Dividend & Shareholder Information
| Metric | RGNT | Rank |
|---|---|---|
| Shares Outstanding | 5M | – |
Balance Sheet Highlights (USD millions)
| Cash & Short-term Investments | $7M | |
| Total Liabilities | $3M | 59.9% of assets |
RGNT quarterly financials and insider trading
Regentis Biomaterials Ltd. (RGNT) industry peers
Companies classified under the same SEC industry code as Regentis Biomaterials Ltd. (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| RGNT Regentis Biomaterials Ltd. | ▶ | $8M |
| ISRG Intuitive Surgical Inc | ▼ | $149.10B |
| SNN Smith & Nephew Plc | ▼ | $24.29B |
| STE Steris Plc | ▼ | $21.35B |
| ZBH Zimmer Biomet Holdings, Inc. | ▼ | $17.58B |
| ALGN Align Technology Inc | ▶ | $10.20B |
| MSA Msa Safety Inc | ▼ | $7.01B |
| ESTA Establishment Labs Holdings Inc. | ▲ | $1.74B |
| CDRE Cadre Holdings, Inc. | ▲ | $1.12B |
| ENOV Enovis Corp | ▶ | $1.10B |
| AVR Anteris Technologies Global Corp. | ▼ | $629M |
| SMTI Sanara Medtech Inc. | ▼ | $323M |
| INGN Inogen Inc | ▶ | $168M |
| LAKE Lakeland Industries Inc | ▲ | $97M |
| NTRB Nutriband Inc. | ▲ | $71M |
| APT Alpha Pro Tech Ltd | ▲ | $59M |
| MYO Myomo, Inc. | ▲ | $51M |
| COCH Envoy Medical, Inc. | ▲ | $50M |
| MLSS Milestone Scientific Inc. | ▲ | $31M |
| LFWD Lifeward Ltd. | ▲ | $18M |
| UEEC United Health Products, Inc. | ▶ | $12M |
| CLGN Collplant Biotechnologies Ltd | ▶ | $5M |
| RBOT Vicarious Surgical Inc. | ▶ | $360K |
| FEED Envue Medical, Inc. | ▼ | $320K |
| BBLG Bone Biologics Corp | ▶ | N/A |
| CUPR Cuprina Holdings (Cayman) Ltd | ▼ | N/A |
| LGMK Logicmark, Inc. | ▶ | N/A |
Where RGNT sits on the market map
Regentis Biomaterials Ltd. (RGNT) stock news
Loading...
Regentis Biomaterials Ltd. (RGNT) stock forecast FAQ
What is the Regentis Biomaterials Ltd. (RGNT) stock forecast?
On Oct. 13, 2026, RGNT is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Regentis Biomaterials Ltd. stock predictions?
A per-ticker accuracy statistic for RGNT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Regentis Biomaterials Ltd. forecasts updated?
Regentis Biomaterials Ltd. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Regentis Biomaterials Ltd.'s industry peers?
27 issuers in our coverage, RGNT included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Smith & Nephew Plc (SNN), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Align Technology Inc (ALGN), Msa Safety Inc (MSA).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.